Abstract
Ketoconazole pharmacokinetics were determined in nine adults with haematological malignancy after one week on a 200 mg daily dose and later after one week on a 400 mg daily dose. The area under the serum concentration time curve (AUC) reached 12.3 ± 7.7 mg/l.h (mean ± S.D.) on the 200 mg dose and increased to 23.0 ± 18.2 mg/l.h on the 400 mg dose (p < 0.05). The half-life of ketoconazole was 3.1 + 1.9 h on the 200 mg dose and 3.5 ± 1.7 h on the 400 mg dose. Peak concentrations were 3.2 ±1.8 mg/l and 4.6 ± 3.2 mg/l on the 200 mg and 400 mg doses, respectively. Trough ketoconazole concentrations were undetectable 24 h after either dose. There was no correlation between the leucocyte count and any pharmacokinetic parameter for ketoconazole. Variation in AUC was 20-fold on the 200 mg daily dose and 8-fold on the 400 mg per day regimen. Measurement of serum levels during ketoconazole treatment appears necessary in view of the unpredictable concentrations achieved. Once-a-day dosage regimens of ketoconazole in immunocompromised patients may be inappropriate. Future clinical trials should adopt a two or three times a day dosing regimen, as this may confer a pharmacokinetic and therapeutic advantage.
Similar content being viewed by others
References
Levine, H. B. (ed): Ketoconazole in the management of fungal disease. ADIS Press, Sydney, 1982.
Heel, R. C., Brogden, R. N., Carmine, A., Morley, P. A., Speight, T. M., Avery, G. S.: Ketoconazole: a review of its therapeutic efficacy in systemic fungal infections. Drugs 1982, 23: 1–36.
Hann, I. M., Prentice, H. G., Corringham, R., Blacklock, H. A., Keaney, M., Shannon, M., Noone, P., Gascoigne, E., Fox, J., Boesen, E., Szawatkowski, M., Hoffbrand, A. V.: Ketoconazole versus nystatin plus amphotericin B for fungal prophylaxis in severely immunocompromised patients. Lancet 1982, i: 826–829.
Donnelly, J. P., Starke, I. D., Galton, D. A. G., Catovsky, D., Goldman, J. M., Darrell, J. H.: Oral ketoconazole and amphotericin B for prevention of yeast colonization in patients with acute leukaemia. Journal of Hospital Infection 1984, 5: 83–93.
Jones, P. G., Kauffman, C. A., McAuliffe, L. S., Liepman, M. K., Bergman, A. G.: Efficacy of ketoconazole v nystatin in prevention of fungal infections in neutropenic patients. Archives of Internal Medicine 1984, 144: 549–551.
Hann, I. M., Prentice, H. G., Keaney, M., Corringham, R., Blacklock, H. A., Fox, J., Gascoigne, E., van Cutsem, J.: The pharmacokinetics of ketoconazole in severely immunocompromised patients. Journal of Antimicrbial Chemotherapy 1982, 10: 489–496.
Maksymiuk, A. M., Levine, H. B., Bodey, G. P.: Pharmacokinetics of ketoconazole in patients with neoplastic disease. Antimicrobial Agents and Chemotherapy 1982, 22: 43–46.
Vu Van, H., Piens, M. A., Archimbaud, E., Monier, M. F., Goyotat, D., Mojon, M., Fiere, D.: Serum levels of ketoconazole in bone marrow transplanted patients. Nouvelle Revue Francaise d'Hematologie 1983, 25: 241–244.
Daneshmend, T. K., Warnock, D. W., Turner, A., Roberts, C. J. C.: Pharmacokinetics of ketoconazole in normal subjects. Journal of Antimicrobial Chemotherapy 1981, 8: 299–304.
Daneshmend, T. K., Warnock, D. W., Ene, M. D., Johnson, E. M., Potten, M. R., Richardson, M. D., Williamson, P. J.: Influence of food on the pharmacokinetics of ketoconazole. Antimicrobial Agents and Chemotherapy 1984, 25: 1–3.
Daneshmend, T. K., Warnock, D. W., Ene, M. D., Johnson, E. M., Parker, G., Richardson, M. D., Roberts, C. J. C.: Multiple dose pharmacokinetics of ketoconazole and their effects on antipyrine kinetics in man. Journal of Antimicrobial Chemotherapy 1983, 12: 185–188.
van der Meer, J. W. M., Keuning, J. J., Scheijgrond, H. W., Heykants, J., van Cutsem, J., Brugmans, J.: Influence of gastric acidity on the bioavailability of ketoconazole. Journal of Antimicrobial Chemotherapy 1980, 6: 522–524.
Brass, C., Galgiani, J. N., Blaschke, T. F., Defelice, R., O'Reilly, R. A., Stevens, D. A.: Disposition of ketoconazole, an oral antifungal, in humans. Antimicrobial Agents and Chemotherapy 1982, 21: 151–158.
Graybill, J. R., Craven, P. C., Donovan, W., Matthew, E. B.: Ketoconazole therapy for systemic fungal infections: inadequacy of standard dose regimens. American Review of Respiratory Disease 1982, 126: 171–174.
Trachtenberg, J., Pont, A.: Ketoconazole therapy for advanced prostate cancer. Lancet 1984, ii: 433–435.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Stockley, R.J., Daneshmend, T.K., Bredow, M.T. et al. Ketoconazole pharmacokinetics during chronic dosing in adults with haematological malignancy. Eur. J, Clin. Microbiol. 5, 513–517 (1986). https://doi.org/10.1007/BF02017693
Issue Date:
DOI: https://doi.org/10.1007/BF02017693